Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
This research trial, called TripleTRE, is looking at the best way to start treatment for people with a condition called pulmonary arterial hypertension (PAH), which causes high blood pressure in the lungs. It compares two different treatment approaches for adult patients who are newly diagnosed or haven't been treated for PAH before. One group receives a combination of three medicines: two oral tablets and one medicine (treprostinil) given by injection. The other group receives two oral tablets, which is a common starting treatment. The main goal is to see which treatment helps more patients achieve a 'low risk' status, meaning their condition is better managed. This study will help doctors improve care for PAH patients.
En un coup d'œil
De quoi parle cette étude ?
Pulmonary arterial hypertension, or PAH, is a serious condition where the blood pressure in the arteries leading to your lungs becomes too high. This makes your heart work much harder and can lead to serious health problems. Doctors are always looking for the best ways to treat PAH and help patients live better lives. This study, called TripleTRE, is exploring whether starting treatment with a combination of three medicines might be more effective than starting with two for certain patients.
Currently, many patients with PAH start treatment with two oral medicines. These medicines work in different ways to relax blood vessels in the lungs and lower blood pressure. TripleTRE is investigating whether adding a third medicine, treprostinil (which is given by injection), right from the start can lead to better outcomes, especially for patients with a higher risk level or more severe symptoms.
This trial is for adults with specific types of PAH who are newly diagnosed or haven't received PAH treatment in the past three months. Researchers will carefully monitor how patients respond to their assigned treatment over several months to understand the safety and effectiveness of each approach. The results could help doctors decide the best way to begin treatment for future PAH patients.
Points clés
- Compares two starting treatments for PAH: two pills vs. two pills plus an injected medicine.
- Aims to find out which approach leads to better health for PAH patients.
- Involves adults (18-70) with specific types of newly diagnosed or untreated PAH.
- Participation lasts between 6 months and a year with regular hospital visits.
- You will know which treatment you are receiving (it's 'open-label').
Qui peut être éligible ?
This study is looking for adults aged between 18 and 70 years old who have just been diagnosed with certain types of pulmonary arterial hypertension (PAH) or haven't been treated for it in the last three months. These types include PAH that doesn't have a clear cause (idiopathic), PAH that runs in families (hereditary), PAH caused by medicines or toxins, PAH linked to connective tissue diseases, or PAH with a repaired heart defect from birth.
You might be able to join if your PAH is considered 'intermediate-high risk' or 'intermediate-low risk' but with some severe signs of how your heart and lungs are working. Doctors will do some tests, including a special heart catheterisation, to check your heart and lung pressures and confirm your diagnosis.
However, you won't be able to join if you have certain other types of PAH (like those linked to schistosomiasis, HIV, liver problems, or a widespread skin condition called diffuse systemic sclerosis) or if your heart defect from birth hasn't been fixed. You also can't participate if you've already had PAH-specific treatment recently, if your PAH responds to certain tablets called calcium channel blockers, or if you have certain other lung or heart conditions.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous entre 18 et 70 ans ?
- Have you been diagnosed with PAH recently, or have you not taken PAH medicines in the last 3 months?
- Is your PAH one of these types: idiopathic, hereditary, drug/toxin-induced, associated with connective tissue disease, or with corrected congenital heart disease?
- Are you able to use reliable contraception if you're a woman who could become pregnant?
En quoi consiste la participation ?
If you decide to take part in the TripleTRE study, you'll be randomly assigned to one of two treatment groups, like flipping a coin. You'll receive either two oral medications or the same two oral medications along with treprostinil, which is given by an injection. All medicines will be started within three weeks of joining the study. You'll have regular visits to the hospital for check-ups, tests, and to monitor how you're feeling and how the treatment is working. This will include blood tests, heart and lung function tests, and possibly repeats of the heart catheterisation. The study will follow your progress for about 24 to 48 weeks, which is roughly between six months and a year.
Risques et avantages potentiels
Emplacements (19)
- Ordensklinikum LinzCode postal vérifiéLinz, Autriche· Recrutement
- Medical University ViennaCode postal vérifiéVienne, Autriche· Recrutement
- Fakultní Nemocnice OlomoucCode postal vérifiéOlomouc, Czechia· Pas encore en recrutement
- Všeobecná fakultní nemocnice v PrazeCode postal vérifiéPrague, Tchéquie· Pas encore en recrutement
- Hôpital Bicêtre-- Assistance Publique Hopitaux de ParisCode postal vérifiéParis, France· Pas encore en recrutement
- Hôpitaux Universitaires de StrasbourgCode postal vérifiéStrasbourg, France· Pas encore en recrutement
- DRK Kliniken Berlin WestendCode postal vérifiéBerlin, Allemagne· Pas encore en recrutement
- University Hospital Carl Gustav Carus of Technical University DresdenCode postal vérifiéDresde, Allemagne· Pas encore en recrutement
- Universitätsmedizin GreifswaldCode postal vérifiéGreifswald, Germany· Pas encore en recrutement
- Gottsegen National Cardiovascular lnstituteCode postal vérifiéBudapest, Hungary· Pas encore en recrutement
- Medical University of SzegedCode postal vérifiéSzeged, Hungary· Pas encore en recrutement
- Sapienza University of RomeCode postal vérifiéRome, Italy· Recrutement
Questions fréquentes
What is PAH?
PAH stands for pulmonary arterial hypertension. It's a condition where the blood pressure in the arteries that carry blood from your heart to your lungs is too high, making your heart work harder.
What kind of medicines are being tested?
The study is testing combinations of medicines. Both groups will get two oral medicines. One group will also get an additional medicine called treprostinil, which is given by injection.
Combien de temps l'étude durera-t-elle pour moi ?
If you join the study, your treatment and monitoring will last for approximately 6 to 12 months (24 to 48 weeks).
Saurai-je quel traitement je reçois ?
Yes, this is an 'open-label' study, which means both you and your doctor will know whether you are receiving the two oral medicines or the three-medicine combination.
Do I have to pay to be in the study?
No, all study-related treatments and tests are provided at no cost to you.
Comment en savoir plus
Clinical Project Manager
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.